Clifford Stephan

May 26, 2024 | nature.com | Reid T. Powell |Amanda Rinkenbaugh |Xiaomei Zhang |Yuan Qi |Clifford Stephan |Peter J Davies | +2 more

AbstractTriple negative breast cancer (TNBC) accounts for 15–20% of breast cancer cases in the United States. Systemic neoadjuvant chemotherapy (NACT), with or without immunotherapy, is the current standard of care for patients with early-stage TNBC. However, up to 70% of TNBC patients have significant residual disease once NACT is completed, which is associated with a high risk of developing recurrence within two to three years of surgical resection.